Skip to main content

Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming.

Publication ,  Journal Article
Philbrook, P; Dean, MJ; Sanchez-Pino, MD; Zheng, LQ; Zabaleta, J; Vázquez-Martínez, JA; Chang, D; Mandula, JK; Shaw, TI; Wyczechowska, D ...
Published in: Cancer Immunol Res
April 2, 2026

G protein-coupled receptor 84 (GPR84) is a medium-chain free fatty acid receptor predominantly expressed in myeloid cells. Previous studies have identified GPR84 as an enhancer of the pro-inflammatory myeloid cell responses and a regulator of metabolic homeostasis. However, the role of GPR84 in T-cell function and metabolism remains largely unexplored. This study tested the effect of GPR84 modulation on CD8+ T-cell function and metabolism in vitro and examined its effect on antitumor function in adoptive cellular therapy models. Pharmacologic antagonism with GLPG1205 or genetic deletion of GPR84 promoted T-cell differentiation, proliferation, cytokine production, and cytotoxicity, whereas agonism with DL175 reduced these functions. These functional changes were paralleled by changes in metabolic activity. Antagonism and genetic deletion increased glucose uptake, glycolysis, oxidative phosphorylation, and ATP production, which enhanced the overall cell energetic fitness, whereas agonism resulted in a quiescent energetic profile. Furthermore, antagonism or deletion of GPR84 in antigen-specific CD8+ T cells in adoptive cellular therapy models enhanced their antitumor effects in vivo. Thus, GPR84 inhibition improves CD8+ T-cell function and may further enhance adoptive cellular therapies.

Duke Scholars

Published In

Cancer Immunol Res

DOI

EISSN

2326-6074

Publication Date

April 2, 2026

Volume

14

Issue

4

Start / End Page

640 / 657

Location

United States

Related Subject Headings

  • T-Lymphocytes, Cytotoxic
  • Receptors, G-Protein-Coupled
  • Mice, Knockout
  • Mice, Inbred C57BL
  • Mice
  • Metabolic Reprogramming
  • Immunotherapy, Adoptive
  • Humans
  • Cell Line, Tumor
  • CD8-Positive T-Lymphocytes
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Philbrook, P., Dean, M. J., Sanchez-Pino, M. D., Zheng, L. Q., Zabaleta, J., Vázquez-Martínez, J. A., … Ochoa, A. C. (2026). Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming. Cancer Immunol Res, 14(4), 640–657. https://doi.org/10.1158/2326-6066.CIR-25-0695
Philbrook, Phaethon, Matthew J. Dean, Maria Dulfary Sanchez-Pino, Li Qin Zheng, Jovanny Zabaleta, Julio A. Vázquez-Martínez, Darwin Chang, et al. “Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming.Cancer Immunol Res 14, no. 4 (April 2, 2026): 640–57. https://doi.org/10.1158/2326-6066.CIR-25-0695.
Philbrook P, Dean MJ, Sanchez-Pino MD, Zheng LQ, Zabaleta J, Vázquez-Martínez JA, et al. Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming. Cancer Immunol Res. 2026 Apr 2;14(4):640–57.
Philbrook, Phaethon, et al. “Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming.Cancer Immunol Res, vol. 14, no. 4, Apr. 2026, pp. 640–57. Pubmed, doi:10.1158/2326-6066.CIR-25-0695.
Philbrook P, Dean MJ, Sanchez-Pino MD, Zheng LQ, Zabaleta J, Vázquez-Martínez JA, Chang D, Mandula JK, Shaw TI, Wyczechowska D, Garai J, Thylur Puttalingaiah R, Mansouri A, Huang W, Das S, Chang S, Conejo-Garcia JR, Rodriguez PC, Ochoa AC. Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming. Cancer Immunol Res. 2026 Apr 2;14(4):640–657.

Published In

Cancer Immunol Res

DOI

EISSN

2326-6074

Publication Date

April 2, 2026

Volume

14

Issue

4

Start / End Page

640 / 657

Location

United States

Related Subject Headings

  • T-Lymphocytes, Cytotoxic
  • Receptors, G-Protein-Coupled
  • Mice, Knockout
  • Mice, Inbred C57BL
  • Mice
  • Metabolic Reprogramming
  • Immunotherapy, Adoptive
  • Humans
  • Cell Line, Tumor
  • CD8-Positive T-Lymphocytes